TMPRSS2 and prostate cancer: The discovery of the chromosomal rearrangement leading to TMPRSS2-ERG fusion oncogene, present in more than 50% cases of prostate cancers, has opened important diagnostic and therapeutic perspectives for the treatment of one of the most frequent epithelial tumours in men.